secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001140361-23-045178
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant announces positive initial Phase 1 data for IMVT-1402; IgG reduction without albumin or LDL-C changes
--------------------------------------------------------------------------------

- SC doses of IMVT-1402 achieved peak IgG reductions similar to batoclimab with no decrease in serum albumin or increase in LDL-C.
- In 300 mg MAD cohort, mean total IgG reduction from baseline was 63% after 4 weekly doses; no albumin drop or LDL-C rise observed.
- All adverse events were mild or moderate; no significant albumin reduction or LDL-C increase at any timepoint (all p>0.05).
- Dosing for 600 mg MAD cohort has recently begun; additional MAD data expected in November 2023.
- IMVT-1402 delivered as simple 2 mL SC injection at 150 mg/mL; SAD data showed potency similar to or greater than batoclimab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123045178/0001140361-23-045178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123045178/ef20011235_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-045178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer